---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041326"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:41:18.949114+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ORIC Q2 2023 cash $273.7M, $85M private placement; clinical data milestones set

## Summary
- Cash and investments $273.7M as of June 30, 2023; expected to fund operating plan into late 2025.
- Completed $85M private placement with Nextech, EcoR1, Frazier, Venrock, Boxer investors.
- Initial Phase 1b data for ORIC-114 at ESMO Oct 20-24, 2023; ORIC-533 data Q4 2023; ORIC-944 data Q1 2024.
- R&D expenses $18.8M in Q2 2023 vs $13.8M in Q2 2022, increase due to program advancement and personnel.

## SEC filing metadata
- accession: 0000950170-23-041326
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000095017023041326/0000950170-23-041326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000095017023041326/oric-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041326
- JSON: https://secwatch.observer/filing/0000950170-23-041326.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041326.txt

## Key facts
- Earnings Releases
  Oric Pharmaceuticals, Inc. reported financial results for the fiscal quarter ended June 30, 2023.
  - Period: the fiscal quarter ended June 30, 2023
  - Result: reported results
  source text: ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796280/000095017023041326/0000950170-23-041326-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.